Compare Merck & Co., Inc. (MRK) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Veritone Inc — how do they compare? Merck & Co., Inc. trades at $148.16 (market cap $363.98B), while Veritone Inc trades at $0.87 (market cap $85.83M). The key difference: Merck & Co., Inc. is far larger — about 4240.7× Veritone Inc's market cap, and Merck & Co., Inc. pays a 2.3% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| MRK | VERI | |
|---|---|---|
Market Cap | $363.98B | $85.83M |
Sector | Health | Technology |
52-Week High | $156.43 | $8.39 |
52-Week Low | $77.60 | $0.79 |
Enterprise Value | $410.75B | $121.22M |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Veritone (VERI) trades at $0.9155, up 0.99% on the day, amid a bearish technical signal and negative earnings trends. The company reported a net loss of $111.73 million in 2025, with revenue of $92.19 million, and has missed earnings expectations in recent quarters. Recent news includes a securities class action investigation and partnerships to expand AI solutions.
Outlook remains challenged by persistent losses and legal overhangs, though cost reduction efforts and AI partnerships offer potential growth. Investment risks include high cash burn, negative margins, and shareholder litigation. Analyst sentiment is mixed with a slight buy bias, but fundamental weakness limits near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
